Compare NHC & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NHC | STOK |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | N/A | 2019 |
| Metric | NHC | STOK |
|---|---|---|
| Price | $134.77 | $35.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $34.10 |
| AVG Volume (30 Days) | 90.0K | ★ 865.6K |
| Earning Date | 02-26-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.48 | 0.68 |
| Revenue | ★ $1,500,618,000.00 | $205,632,000.00 |
| Revenue This Year | N/A | $430.24 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $20.20 | $47.54 |
| Revenue Growth | 22.67 | ★ 1128.17 |
| 52 Week Low | $89.14 | $5.35 |
| 52 Week High | $144.53 | $38.69 |
| Indicator | NHC | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 63.10 |
| Support Level | $129.44 | $29.75 |
| Resistance Level | $139.53 | $32.50 |
| Average True Range (ATR) | 3.74 | 1.70 |
| MACD | -1.30 | -0.02 |
| Stochastic Oscillator | 32.81 | 100.00 |
National Healthcare Corp Provides long-term care facilities. Its principal business includes the operation of skilled nursing facilities, assisted living facilities, independent living facilities, and home care programs. The company's activities include providing sub-acute and post-acute skilled nursing care, intermediate nursing care, rehabilitative care, memory and Alzheimer's care, senior living services, and home health care services. In addition, the company also provides management services, accounting, and financial services, as well as insurance services to third-party operators of healthcare facilities. Its reportable segments include Inpatient services, and Home care hospice services. Generating, a majority of its revenue from Inpatient services.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.